In a report released today, Michael Petusky from Barrington maintained a Buy rating on SurModics (SRDX), with a price target of $64. The company’s shares opened today at $47.
Petusky commented:
“We are maintaining our OUTPERFORM investment rating on SRDX and our price target remains $64. We arrive at our price target by using a sum-of-the-parts methodology that assigns $38.50 per share for the core business, $11.00 for the company’s DCB assets, $11.00 for the 510(k) products program and $3.25 per share representing SRDX’s net cash figure.”
According to TipRanks.com, Petusky is a 4-star analyst with an average return of 4.6% and a 51.7% success rate. Petusky covers the Healthcare sector, focusing on stocks such as Anika Therapeutics Inc, Varian Medical Systems, and Merit Medical Systems.
SurModics has an analyst consensus of Strong Buy, with a price target consensus of $68.
See today’s analyst top recommended stocks >>
The company has a one-year high of $82.35 and a one-year low of $38.06. Currently, SurModics has an average volume of 113.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
SurModics, Inc. engages in the provision of medical device and in vitro diagnostic technologies to the healthcare industry. It operates through the Medical Device and In Vitro Diagnostics segments.
